MEMORANDUM

Agenda Item 5(F) Supplement

TO: Honorable Chairwoman Rebeca Sosa, and Members, Board of County Commissioners

DATE: October 7, 2014

FROM: Honorable Harvey Ruvin, Clerk
Circuit and County Courts

Christopher Agrippa, Director
Clerk of the Board Division

SUBJECT: Resolution codesignating SW 56th Street/ Miller Drive from SW 99th Avenue to SW 102nd Avenue as "Kyan Braxton Quintana Way"

Pursuant to Ordinance No. 13-29 of the Miami-Dade County Code, the Commission Auditor shall complete background research on any person, place, or thing that is the subject of a naming, renaming, or designation item or an item approving the co-designation of state or municipal roads, and shall prepare a report detailing the findings of said research prior to the Commission meeting during which the item is scheduled to be considered.

Attached for your information and review is the Commission Auditor's findings regarding Item 5(F) on today's agenda, Resolution codesignation SW 56th Street/ Miller Drive from SW 99th Avenue to SW 102nd Avenue as "Kyan Braxton Quintana Way".

CA/fcd

BOARD OF COUNTY COMMISSIONERS
OFFICE OF THE COMMISSION AUDITOR

MEMORANDUM

TO: Honorable Chairwoman Rebeca Sosa
and Members, Board of County Commissioners

FROM: Charles Anderson
Commission Auditor

DATE: October 7, 2014

SUBJECT: **RESOLUTION CODESIGNATING SW 56th STREET/ MILLER DRIVE FROM SW 99th AVENUE TO SW 102nd AVENUE AS "KYAN BRAXTON QUINTANA WAY"**

Ordinance No. 13-29, adopted on April 2, 2013, requires the Office of the Commission Auditor (OCA) to complete background research on any person, organization, place or thing that is the subject of a naming, renaming or codesignation item.

In accordance with the Ordinance, we are providing this report as a supplement to the Board of County Commissioners (BCC) Agenda Item 5(F).

Pursuant to Ordinance No. 13-29, the OCA completed background research regarding BCC Agenda Item 5(F), Resolution codesignating SW 56th Street/Miller Drive from SW 99th Avenue as "Kyan Braxton Quintana Way", and there were no adverse findings.